Two Sigma Advisers’s SELLAS Life Sciences SLS Stock Holding History

Two Sigma Advisers’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-76,554	Closed	-$289K	–	1819
2025 Q4	$289K	Buy	+76,554	New	+$149K	﹤0.01%	1995

Other funds holding SLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Two Sigma Advisers's SLS Position: Q1 2026 in Review

Two Sigma Advisers sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 76,554 shares — an estimated $289K sold.

Two Sigma Advisers first reported a position in SLS in Q4 2025 and held it in 1 quarter. The position peaked at $289K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

Two Sigma Advisers reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 76,554 SELLAS Life Sciences shares in Q1 2026, an estimated $289K.
Two Sigma Advisers first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 1 quarter.
Two Sigma Advisers's SELLAS Life Sciences position peaked at $289K in Q4 2025.
160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.